Research & Discovery


R2 Innovations research and discovery involves the development of cannabis derivatives/formulations, extracted and derived from  proprietary strains of marijuana. The extracted Cannabidiol / CBD's, combined with proprietary natural ingredient medicines will improve bronchial hyper reactivity (BHR) and lung function in adult asthmatic patients, utilizing three different treatment delivery systems; a metered dose inhaler, sub-lingual (single dose applications, which diffuse into the blood through tissues under the tongue.) and medical nebulizers.
Our General Investigative plan places emphasis on assembling a metered dose inhaler, with components manufactured by companies including, 3M, Presspart and Aptar Corporation, leaders in medical pharmaceutical grade, ingredients canisters, valves and actuaters (metered dose inhaler components). These components require a specific, viscosity medicine (CBD, botanical's from the marijuana plant) as manufactured by our laboratories, Super-critical CO2 extracting processes, where users activating the device receive a measured dose of medication inhaled by the patient.

Our research partners, physicians at National Jewish Health, the number one respiratory hospital in the United States, botanical genetic research experts, leaders in cannabis cultivation, Supercritical CO2 extraction and business management professionals, are devoted to the clinical testing, studies and trials to deliver the first of its kind, FDA approved asthmatic, phytocannabinoid based, metered dose inhaler.

We are on a mission and share one vision; to overcome bronchial hyper reactivity (BHR) and improve lung function in asthmatic patients worldwide. We can achieve this goal without the concerns and known side effects of pharmaceutical rescue inhalers that exist today, including but not limited to the products; fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide and fluticasone rescue inhalers.

Share by: